Cargando…

Efficacy and Safety of SGLT2 Inhibitors in Diabetic Kidney Transplant Patients: Review of the Current Literature

Introduction: SGLT2 inhibitors are oral hypoglycemic medications used in type 2 diabetes mellitus (T2DM). They act by blocking glucose and sodium reabsorption in the proximal renal tubules. In patients with T2DM and cardiovascular disease, SGLT2 inhibitors have been shown to improve glycemic control...

Descripción completa

Detalles Bibliográficos
Autores principales:	Shuster, Shirley, Al-Hadhrami, Zeyana, Awad, Sara, Moore, Sarah, Shamseddin, Khaled
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2021
Materias:	Diabetes Mellitus and Glucose Metabolism
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8265930/ http://dx.doi.org/10.1210/jendso/bvab048.838

Ejemplares similares

Current Utilization Trends of SGLT-2 Inhibitors in Type 2 Diabetics With Heart Failure
por: Dhillon, Puneet, et al.
Publicado: (2021)

Euglycemic Diabetic Ketoacidosis With SGLT-2 Inhibitor
por: Manas, F N U, et al.
Publicado: (2021)

Euglycemic DKA Associated With SGLT2 Inhibitors
por: TakallooBakhtiari, Asieh, et al.
Publicado: (2021)

Precipitation of Euglycemic DKA (euDKA) From the Initiation of SGLT2 Inhibitor (SGLT2i) and 0-Carb Diet Inpatient
por: Popli, Rakesh, et al.
Publicado: (2021)

SUN-180 Successful Use of SGLT-2 Inhibitor Dapagliflozin in Three Patients with Renal Transplant and Diabetes: A Fruit for Thoughts
por: Elhadd, Tarik, et al.
Publicado: (2019)

Euglycemic DKA in Patients on SGLT2 Inhibitor and Potentially Ketotic State
por: Khalifa, Maram, et al.
Publicado: (2021)

SUN-177 House Of Carbs: The Path To Euglycemic Dka In Patients With Diabetes On Sglt2 Inhibitors
por: Islam, Julie, et al.
Publicado: (2019)

MON-690 Euglycemic Diabetic Ketoacidosis Associated with SGLT-2 Inhibitors- an Under-recognized Diagnosis
por: Chhabra, Sarah, et al.
Publicado: (2020)

A Case of Euglycemic DKA With SGLT 2 Inhibitor Use- A Diagnostic and Therapeutic Dilemma
por: Nallu, Ravali, et al.
Publicado: (2021)

A Case Report of Euglycemic Diabetic Ketoacidosis in the Setting of Keto Diet and SGLT-2 Inhibitors
por: Marenych, Nadiia, et al.
Publicado: (2021)

Euglycemic Diabetic Ketoacidosis Secondary to SGLT2-inhibitor Use in Combination With a Ketogenic Diet
por: Hester, Joi C, et al.
Publicado: (2021)

SAT-685 Euglycemic Diabetic Ketoacidosis in T1d: The Era of SGLT-2 Inhibitors and Keto-Diet
por: Castellanos-Diaz, Jessica, et al.
Publicado: (2020)

MON-LB123 Diagnosis and Management of Euglycemic DKA in the Setting of SGLT2 Inhibitor Use and Prostate Abscess
por: Rameshkumar, Naveen Sundar
Publicado: (2020)

Euglycemic Diabetic Ketoacidosis Post Bariatric Surgery in Type II DM in the Setting of SGLT2-Inhibitor Use
por: Alfares, Khalid, et al.
Publicado: (2021)

OR22-1 Liraglutide as Add-on to SGLT2 Inhibitors in Patients with Inadequately Controlled Type 2 Diabetes (LIRA-ADD2SGLT2i): A 26-Week, Randomized, Double-Blind, Placebo-Controlled Trial
por: Blonde, Lawrence, et al.
Publicado: (2019)

Clinical And Biochemical Outcomes Of Sodium-Glucose Co-Transporter-2 (SGLT2) Inhibitors In Type 2 Diabetes Mellitus Patients
por: Saleem, Muhammad, et al.
Publicado: (2021)

SUN-181 Case Report: Rare Complication of SGLT2 Inhibitors Can Occur Only 10 Days after Starting the Medication
por: Elshimy, Ghada, et al.
Publicado: (2019)

SUN-155 Clinical Experience of SGLT2 Inhibitors in a Hispanic Population: Should We Consider Its Use as Add-On Treatment?
por: Zayas, Francisco, et al.
Publicado: (2019)

SUN-672 SGLT2 Inhibitor Reduces Hyperinsulinemia and Restores Pulsatile Growth Hormone Secretion in Obese MC4RKO Mice
por: Huang, Zhengxiang, et al.
Publicado: (2020)

SUN-176 Euglycemic Diabetic Ketoacidosis withSGLT2 Inhibitor Presenting as Chest Pain in a Patient with Coronary Artery Disease on a Ketogenic Diet
por: Dorcely, Brenda, et al.
Publicado: (2019)

SAT-662 Effects of SGLT Inhibitors or GLP1 Analogues on Glucose Homeostasis and Body Weight in Patients with Type 1 Diabetes: A Network Meta-Analysis
por: Lim, Soo, et al.
Publicado: (2020)

ODP242 Safety of SGLT2-Inhibitors in Patients with Multiple Myeloma and Diabetes
por: Shyu, Margaret, et al.
Publicado: (2022)

MON-652 The Prevalence and Clinical Characteristics of Adult Patients Presenting with Sodium-Glucose Co-Transporter-2 Inhibitor Associated Euglycemic Diabetic Ketoacidosis
por: Clark, Alexa, et al.
Publicado: (2020)

MON-694 EDKA and MALA in the Setting of Severe Heart Failure and Acute Renal Failure, Due to SGLT2-i
por: Heckart, Jonathan Calvin, et al.
Publicado: (2020)

Sodium Glucose Co-Transporter2 (SGLT2) Inhibition for Refractory Hypomagnesemia in Monogenic Diabetes Type 5 (MODY 5)
por: Paul, Anju A, et al.
Publicado: (2021)

MON-LB029 The Influence of SGLT-2 Inhibitors and Other Glucose-Lowering Therapies on All-Cause Mortality Risk and Cardiovascular Outcomes in Older Patients with Newly Treated Type 2 Diabetes: A Population-Based Cohort Study
por: Doyle, Mary-Anne, et al.
Publicado: (2019)

A Possible Advantage of Glucagon-Like Peptide 1 Receptor Agonist in Kidney Transplant Recipients With Type 2 Diabetes
por: Sato, Tetsuhiko, et al.
Publicado: (2021)

THU387 Euglycemic Diabetic Ketoacidosis And SGLT-2 Inhibitor Use
por: Abrahimi, Nora, et al.
Publicado: (2023)

THU360 Hyperglycemic DKA In Patient On Monotherapy With SGLT-2 Inhibitor
por: Ahmed, Samihah, et al.
Publicado: (2023)

ODP244 SGLT2 Inhibitor-Induced Euglycemic DKA and its Challenges
por: Penna, Laurianne El Musa, et al.
Publicado: (2022)

PSUN190 Is Euglycemic Diabetic Ketoacidosis an Underrecognized Risk of SGLT2 Inhibitor Utilization?
por: Block, Romy, et al.
Publicado: (2022)

SAT087 Maternally Inherited Diabetes And Deafness: Support For SGLT2 Inhibitor Use
por: Pandya, Stuti, et al.
Publicado: (2023)

THU389 Euglycemic Diabetic Ketoacidosis With Prolonged Ketosis Due To SGLT-2 Inhibitor
por: Viera Feliciano, Natalia, et al.
Publicado: (2023)

THU247 Characterizing Inpatient Cases Of DKA Precipitated By SGLT2 Inhibitor Use
por: Aslamy, Arianne, et al.
Publicado: (2023)

Clinical Effectiveness and Safety of Gliclazide MR and Linagliptin Combination in the Management of Patients With T2DM and Chronic Kidney Disease (CKD) Switched From Glimepiride - a Real-World, Retrospective, Observational Study
por: Bhattacharyya, Supratik, et al.
Publicado: (2021)

THU291 Successful Reversal Of Glucose Toxicity After DKA Precipitated By SGLT2 Inhibitor
por: Abdelrahman, Houda, et al.
Publicado: (2023)

Inpatient Hypoglycemia in Patients With Chronic Kidney Disease
por: Do, Justin, et al.
Publicado: (2021)

PSUN263 Diagnosis of Latent Autoimmune Diabetes of Adulthood Unveiled After Initiation of an SGLT2 Inhibitor
por: Patel, Goonja, et al.
Publicado: (2022)

THU359 A Classical Case Of SGLT-2 Inhibitor Euglycemic Ketoacidosis In A Patient With Glucotoxicity
por: Amankwah, Samuel, et al.
Publicado: (2023)

THU287 Comparison Of Renal Protective Effects Between SGLT2 Inhibitors And DPP4 Inhibitors In Real-World Clinical Practice
por: Park, Hyeong-Kyu, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_o6vnlfnrurjf0i91g8s0r6ks44